These and additional ubiquitin-dependent mechanisms have been implicated in TGF-β signaling, and their dysregulation is frequently observed in GBM as well as other cancers, therefore opening new avenues for therapeutic intervention (293). The gene discussed is UBA52; the disease is cancer.